On Mar. 19, 2020, Mesa Biotech announced it had been awarded a $561K contract from the U.S. Department of Health and Human Services (HHS) Biomedical Advanced Research and Development Authority (BARDA) for development of its rapid molecular diagnostic test for detection of SARS-CoV-2 for ‘near patient’ testing.

The Accula SARS-CoV-2 Test was planned to be developed on the company’s commercially available platform for Accula Flu A/Flu B and RSV Test, which were both 510(k) cleared and CLIA waived.